|
Almirall S.A. is a global pharmaceutical company focused on medical dermatology, developing treatments for skin conditions such as psoriasis, atopic dermatitis, and actinic keratosis. Founded in 1944, the company serves patients and healthcare professionals with a portfolio that includes biological therapies, small molecules, and topical treatments. Key products include fumaric acid ester treatments for psoriasis and biologics for moderate-to-severe atopic dermatitis. The company maintains a dedicated R&D center in Barcelona and has expanded its presence through acquisitions of Hermal, Aqua Pharmaceuticals, and Poli Group. Almirall collaborates with partners including Simcere, Absci, and the Barcelona Supercomputing Center to advance skin science and develop new therapeutic solutions. Summarised from the company's own disclosures, fiscal year ended Dec 2025 |
Industry Drug Manufacturers - General | Homepage almirall.com |
| Sector Healthcare | IR page almirall.com | |
|
Tags
medical dermatology, psoriasis, atopic dermatitis, actinic keratosis, biologics, topical treatments, small molecules, skin conditions, r&d, pharmaceuticals, Hermal, Aqua Pharmaceuticals, Poli Group, Simcere, Absci, Barcelona Supercomputing Center, Athenex, Allergan, Dermira, Prodesfarma
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | € 1.695B |
| Market cap (USD) | $ 1.901B |
| P/E | 28.86 |
| PEG | 0.24 |
| P/BV | 1.11 |
| P/S | 1.47 |
| P/OCF | 6.82 |
| P/FCF | 12.15 |
| Dividend yield | 2.4% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 3.1% |
| ROI | 3.9% |
| ROIC | 3.8% |
| Profit margin | 4.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 120.9% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 6 |
| Quality score | 16.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.108B | 985.721M | 894.516M | 863.248M | 827.195M | 807.427M | 855.339M | 756.934M | 639.381M | 764.361M | 684.985M | 786.396M | 692.891M | 682.882M | 768.418M | 882.438M |
| Net profit | 46.154M | 10.147M | 38.474M | 4.281M | 40.859M | 74.28M | 105.909M | 77.674M | -303.961M | 75.479M | 131.826M | 448.429M | -33.717M | 76.291M | 84.166M | 118.604M |
| Free cash flow | 139.549M | 130.932M | 59.986M | 132.095M | 215.038M | 100.866M | — | — | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Balance sheet detail | |||||||
| Trade receivables (EUR) | — | 111M | 128M | 138M | 131M | 151M | 158M |
| ↳ YoY growth | +14.7% | +8.3% | -4.9% | +15.2% | +4.6% | ||
| ↳ 5y CAGR | +7.3% | ||||||
| Lease liabilities (EUR) | — | 19.7M | 20.4M | 39M | 43.8M | 44.6M | 42.3M |
| Cash and deposits (EUR) | 117M | 166M | 207M | 249M | 388M | 377M | 338M |
| Intangible assets (EUR) | — | 1.01B | 916M | 899M | 951M | 937M | 894M |
| Right-of-use assets (EUR) | — | 19.3M | 20M | 38.7M | 43M | 43.6M | 40.8M |
| Cash flow detail | |||||||
| Operating cash flow (EUR) | — | 113M | 234M | 155M | 93.5M | 161M | 174M |
| Purchases of property, plant and equipment (EUR) | — | -11.9M | -18.8M | -23M | -33.5M | -29.8M | -34.9M |
| Purchases of intangible assets (EUR) | — | -64.6M | -52.3M | -93.5M | -126M | -132M | -102M |
| Change in receivables (cash effect) (EUR) | — | -106M | 13.1M | -2.88M | -3.15M | -4.72M | -26.1M |
| Change in inventories (cash effect) (EUR) | — | 25.3M | -13.3M | 10.7M | -37.1M | -3.53M | -7.65M |
| Change in payables (cash effect) (EUR) | — | 57.5M | -11M | -6.27M | -9.39M | 1.05M | 9.38M |
| Dividends paid (cash effect) (EUR) | — | -2.13M | -11.7M | -12.4M | -2.59M | -3.29M | -26.2M |
| Share buybacks (cash effect) (EUR) | — | -82,000 | -596,000 | -46,000 | -157,000 | -539,000 | -1.31M |
| Interest paid (cash effect) (EUR) | — | -6.54M | -6.13M | -9.9M | -10.2M | -10.5M | -11.5M |
| Income taxes paid (cash effect) (EUR) | — | -26.3M | 23.5M | -6.36M | 13.6M | 24.2M | 35.6M |
| Operating cash flow before change in receivables (EUR) | — | 219M | 221M | 158M | 96.6M | 165M | 201M |
| Free cash flow (OCF - PPE - intangibles) (EUR) | — | 36.2M | 163M | 38.6M | -65.8M | -664,000 | 37.2M |
| Income detail | |||||||
| Total comprehensive income (EUR) | — | 25.4M | 5.31M | 45.5M | 50.7M | 27.1M | 21.6M |
| Comprehensive income to owners (EUR) | — | 25.4M | 5.31M | 45.5M | -50.7M | 27.1M | 21.6M |
| Reported | Feb 21, 2022 | Feb 21, 2022 | Feb 21, 2022 | Feb 20, 2023 | Feb 19, 2024 | Feb 24, 2025 | Feb 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpInside information and other relevant information filed with the CNMV, newest first, titles as filed, own-share transactions and liquidity-contract reports included. The link opens the filed document. Press releases from the company's own website, newest first.
Dermatology
-
Other skin conditions
-
Other skin conditions

Published on October 29, 2026
Today, on World Psoriasis Day, we’re looking beyond the visible and raising awareness of the impact psoriasis can have beyond the skin.
In a digital world increasingly shaped by filters and edited images, the realities of living with a visible skin condition can easily go unseen. Psoriasis is visible on the skin, but its psychological burden may be much less apparent and can be an important part of the experienceof people living with the disease.
In collaboration with IFPA, we’re helping bring greater visibility to this often less visible side of psoriasis, encouraging a deeper understanding of the experiences behind the symptoms and the impact the condition can have on people’s lives.
World Psoriasis Day is also an opportunity to listen, learn and continue building awareness around the realities faced by people living with psoriasis.
Because understanding psoriasis meanslooking beyond what we can see.

Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
Allow All
Manage Consent Preferences
Marketing Cookies
Marketing Cookies Inactive
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
Performance Cookies Inactive
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Functional Cookies
Functional Cookies Inactive
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Cookie List
Clear
- checkbox label label
Apply Cancel
Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject All
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding ALMIRALL S.A.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DISV | 0.07% | 317,779 | $ 3.791M | Nov 12, 2026 |
| AVDS | 0.03% | 10,794 | $ 125.757K | Nov 16, 2026 |
| DFIS | 0.03% | 129,956 | $ 1.55M | Nov 12, 2026 |
| DXIV | 0.02% | 3,473 | $ 41.432K | Nov 12, 2026 |
| DFIC | 0.01% | 96,545 | $ 1.152M | Nov 12, 2026 |
| DFSI | 0.01% | 6,423 | $ 76.624K | Nov 12, 2026 |
| DFAI | 0.01% | 85,970 | $ 1.026M | Nov 12, 2026 |
| DFAX | 0.00% | 38,216 | $ 455.904K | Nov 12, 2026 |
| AVDE | 0.00% | 15,281 | $ 178.034K | Nov 16, 2026 |
| AVSD | 0.00% | 958 | $ 11.161K | Nov 16, 2026 |







